Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Datamonitor
|
$175.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$483.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
JAPAN TOBACCO INC Files for New Drug Application for Marketing Approval of Tablet Regimen Containing JTK-303 (elvitegravir) in Japan
JAPAN TOBACCO INC announced that it has filed a New Drug Application (NDA) for marketing approval of a novel anti-HIV single tablet regimen containing JT's original compound JTK-303 (elvitegravir) with the Japanese Ministry of Health, Labour and Welfare.
Latest Developments for Japan Tobacco Inc
- Japan Tobacco Inc Receives Manufacturing and Marketing Approval for Stribild Combination Tablets
- Japan Govt To Sell Japan Tobacco Inc Stake For $7.8 Billion-DJ
- Japan Tobacco Inc Completes Acquisition of Al Nakhla Tobacco Company S.A.E. and Al Nakhla Tobacco Company-Free Zone S.A.E. from BATATA S.A.
- Japan Tobacco Inc Announces Changes in Shareholding Structure
- Share this
- Link this
- Digg this
Follow Reuters